Castle Biosciences, Inc.
NASDAQ:CSTLMedical - Diagnostics & Research
+$0.04 today
- Market cap
- $1.03B
- Beta
- 1.02
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.43
Volume 0.38M
Average 0.37M
CSTL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Castle Biosciences, Inc.NASDAQ: CSTL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $3.93M fell 86.8% year over year, behind the -64.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +57.0% a year.
Context
- Depreciation & amortization amounted to 11.8% of revenue in FY2025, up 7.0 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -86.8% toward the trailing-twelve-month pace of -64.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 40.77M USD
- Year-over-year change
- +154.9%
- 4-year CAGR
- +86.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 40.77M | +154.9% |
| FY2024 | 2024-12-31 | 16M | +29.7% |
| FY2023 | 2023-12-31 | 12.33M | +16.9% |
| FY2022 | 2022-12-31 | 10.54M | +209.5% |
| FY2021 | 2021-12-31 | 3.41M | — |
Depreciation & Amortization vs competitors
How CSTL compares with its peers on the latest reported figures
- CSTL's LTM Mar 2026 depreciation & amortization of $14.94M is the 5th largest of the 8 companies compared; the peer median is $20.83M.
- Its year-over-year change of -64.8% is the lowest of 8, against a peer median of -8.0%.
- Depreciation & amortization amounts to 4.4% of revenue for CSTL, versus a peer median of 6.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.46M | -8.0% | -0.8% | 8.5% | |
| LTM Mar 2026 | $51.8M | -13.5% | +0.6% | 6.2% | |
| LTM Sep 2026 | $39.23M | -2.3% | +3.4% | 3.1% | |
| LTM Jun 2026 | $20.83M | -9.4% | -6.2% | 3.7% | |
| LTM Mar 2026 | $14.94M | -64.8% | +57.0% | 4.4% | |
| LTM Mar 2026 | $9.83M | -8.1% | +6.0% | 15.2% | |
| FY2025 | $9.21M | +14.5% | +23.3% | 8.5% | |
| LTM Mar 2026 | $5.58M | +0.8% | -1.4% | 5.8% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding CSTL) | $20.83M | -8.0% | +0.6% | 6.2% | |
Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.29M) | (67.14M) | (57.47M) | 18.25M | (24.16M) |
| Depreciation & Amortization | 3.41M | 10.54M | 12.33M | 16M | 40.77M |
| Deferred Income Tax | (8.74M) | (1.88M) | (223K) | 1.4M | (6.23M) |
| Stock-Based Compensation | 21.74M | 36.32M | 51.22M | 50.32M | 45.89M |
| Change in Working Capital | (4.1M) | (7K) | (6.63M) | (14.13M) | 13.6M |
| Accounts Receivables | (4.63M) | (6.22M) | (14.93M) | (12.64M) | 6.88M |
| Inventory | 327K | (1.68M) | (3.96M) | (193K) | (2.14M) |
| Accounts Payables | (182K) | 582K | 5.71M | (4.37M) | 3.08M |
| Other Working Capital | 384K | 7.31M | 6.56M | 3.08M | 5.79M |
| Other Non-Cash Items | 0 | (19.5M) | (4.86M) | (6.97M) | (5.53M) |
| Operating Cash Flow | (18.98M) | (41.66M) | (5.63M) | 64.87M | 64.35M |
| Capital Expenditures | (3.48M) | (5.63M) | (13.62M) | (28.33M) | (36.02M) |
| Acquisitions (Net) | (63.18M) | (26.97M) | 0 | 18K | (18.73M) |
| Purchases of Investments | 0 | (134.69M) | (189.08M) | (205.73M) | (188.71M) |
| Sales of Investments | 0 | 0 | 186.5M | 183.9M | 190.73M |
| Other Investing Activities | 10K | 742K | 13K | 0 | (7.64M) |
| Investing Cash Flow | (66.66M) | (166.55M) | (16.18M) | (50.14M) | (60.37M) |
| Debt Repayment | (8K) | (122K) | (142K) | 9.9M | (115K) |
| Common Stock Issued | 0 | 0 | 0 | 2.02M | 2.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.43M | 1.64M | (2.16M) | (5.78M) | (9.05M) |
| Financing Cash Flow | 5.42M | 1.52M | (2.3M) | 6.14M | (6.96M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (80.22M) | (206.69M) | (24.11M) | 20.87M | (2.98M) |
| Free Cash Flow | (22.47M) | (47.29M) | (19.25M) | 36.54M | 28.33M |
Castle Biosciences, Inc.
NASDAQ:CSTL
Intrinsic Alpha fair value
Locked
Current Price
$33.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.